Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 24;22(10):1805.
doi: 10.3390/molecules22101805.

Dermaseptin-PH: A Novel Peptide with Antimicrobial and Anticancer Activities from the Skin Secretion of the South American Orange-Legged Leaf Frog, Pithecopus (Phyllomedusa) hypochondrialis

Affiliations

Dermaseptin-PH: A Novel Peptide with Antimicrobial and Anticancer Activities from the Skin Secretion of the South American Orange-Legged Leaf Frog, Pithecopus (Phyllomedusa) hypochondrialis

Linyuan Huang et al. Molecules. .

Abstract

The dermaseptin peptides, mainly derived from the skin secretions of Hylidae frogs, belong to a superfamily of antimicrobial peptides and exhibit diverse antimicrobial and anticancer activities with low cytotoxicity. Here, we reported a novel dermaseptin peptide, from the South American orange-legged leaf frogs, Pithecopus (Phyllomedusa) hypochondrialis, processing the shortest peptide length, namely Dermaseptin-PH. The complementary DNA (cDNA) encoding biosynthetic precursor of Dermaseptin-PH was initially identified by the rapid amplification of cDNA ends PCR (RACE-PCR) technique from the skin secretion. The predicted primary structure was confirmed by a combination of reverse-phase high performance liquid chromatography (RP-HPLC) and MS/MS fragmentation from the skin secretion. Chemically-synthetic Dermaseptin-PH was investigated using a range of bioactivity assessment assays to evaluate the biological activities and cytotoxicity of Dermaseptin-PH. Dermaseptin-PH inhibited the growth of Gram-negative bacteria, Gram-positive bacteria, and pathogenic yeast Candidaalbicans. In addition, Dermaseptin-PH showed a broad-spectrum of anticancer activities against several cancer cell lines including MCF-7, H157, U251MG, MDA-MB-435S, and PC-3. The potent antimicrobial and anticancer activities of Dermaseptin-PH make it a promising candidate in the discovery of new drugs for clinical applications, and the relatively short sequence of Dermaseptin-PH can provide new insight for the research and structural modification of new peptide drugs.

Keywords: amphibian skin secretion; anticancer; antimicrobial; dermaseptin; molecular cloning.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Nucleotide and translated open-reading frame amino acid sequences of Dermaseptin-PH from the skin secretion of Pithecopus hypochondrialis. The putative signal peptide is double-underlined, the mature peptide is single-underlined, and the stop codon is marked by an asterisk.
Figure 2
Figure 2
Alignments of the amino acid sequences of the prepropeptides of Dermaseptin-1, Dermaseptin-H1, Dermaseptin-H2, and Dermaseptin-PH comprise five domains, 1: putative N-terminal signal peptide region; 2: acidic amino acid rich spacer peptide region; 3: endoproteolytic cleavage point; 4: mature peptide progenitor region; 5: extension of biosynthetic precursor. Amino acid indicated with bold type serves as an amide donor for C-terminal amidation. The identical amino acid residues are indicated by the asterisks.
Figure 3
Figure 3
Alignments of amino acid sequences of Dermaseptin-1 (Accession No. P84596), Dermaseptin-2 (Accession No. P84597), Dermaseptin-3 (Accession No. P84598), Dermaseptin-4 (Accession No. P84599), Dermaseptin-5 (Accession No. P84600), Dermaseptin-6 (Accession No. P84601), Dermaseptin-7 (Accession No. P84880), Dermaseptin-H1 (Accession No. Q0VZ36), Dermaseptin-H2 (Accession No. Q0VZ37) and Dermaseptin-PH derived from the frog Pithecopus hypochondrialis are displayed. The identical amino acids are shaded in black; the amino acid with slight changes are indicated in bold type; the gaps are used to maximise alignments.
Figure 4
Figure 4
Reverse-phase high performance liquid chromatography (RP-HPLC) chromatogram of lyophilised skin secretion of Pithecopus hypochondrialis. The arrow indicates the retention time/elution position of the fraction containing a peptide with a mass coincident with that of Dermaseptin-PH. The absorbance was set at λ = 214 nm. The X-axis indicates the retention time in minutes and the Y-axis indicates the relevant absorbance in arbitrary units.
Figure 5
Figure 5
MS/MS fragmentation datasets derived from ions coincident with the mass of Dermaseptin-PH. Predicted singly and doubly charged b-ions and y-ions arising from MS/MS fragmentation of Dermaseptin-PH. Ions detected by MS/MS fragmentation are indicated in red and blue.
Figure 6
Figure 6
Circular dichroism (CD) spectra of Dermaseptin-PH (50 μM) in 10 mM ammonium acetate/water solution (blue line) and in 50% 2,2,2-trifluoroethanol (TFE)/10 mM ammonium acetate/water solution (red line).
Figure 7
Figure 7
The antimicrobial activities of Dermaseptin-PH against the growth of (a) E. coli; (b) P. aeruginosa; (c) S. aureus; (d) MRSA; (e) E. faecalis; and (f) C. albicans in a range of concentrations from 1 μM to 512 μM. Data represent means ± stand error of the mean (SEM) of 5 replicates.
Figure 7
Figure 7
The antimicrobial activities of Dermaseptin-PH against the growth of (a) E. coli; (b) P. aeruginosa; (c) S. aureus; (d) MRSA; (e) E. faecalis; and (f) C. albicans in a range of concentrations from 1 μM to 512 μM. Data represent means ± stand error of the mean (SEM) of 5 replicates.
Figure 8
Figure 8
The haemolytic activity of Dermaseptin-PH was tested on horse red blood cells. The positive control group was treated with 1% Triton X-100 lysis buffer.
Figure 9
Figure 9
The biofilm formation inhibitory activity of Dermaseptin-PH against (a) E. coli and (b) S. aureus, and the biofilm eradication activity of Dermaseptin-PH against (c) E. coli and (d) S. aureus. Negative control was obtained following incubation with relevant culture medium. Data represent means ± SEM of 5 replicates.
Figure 10
Figure 10
Cell membrane permeability effects of Dermaseptin-PH on (a) E. coli; (b) P. aeruginosa; (c) S. aureus; (d) MRSA; (e) E. faecalis; and (f) C. albicans, by using SYTOX Green (Life technologies, Carlsbad, CA, USA) assay at peptide concentrations corresponding to MIC results. Positive control was obtained following incubation with 70% isopropyl alcohol. Negative control (NC) was obtained following incubation with 5% tryptic soy broth (TSB) in 0.85% NaCl solution. Data represent means ± SEM of 5 replicates. The levels of significance are: * p < 0.05, *** p < 0.001.
Figure 11
Figure 11
The effects of Dermaseptin-PH on proliferation of human cancer cell lines (a) MCF-7; (b) H157; (c) U251MG; (d) MDA-MB-435S; and (e) PC-3 and (f) human dermal microvascular endothelium cell HMEC-1; after treatment with Dermaseptin-PH for 24 h at a range of concentrations from 10−9 to 10−4 M. The levels of significance are: * p < 0.05, *** p < 0.001. The negative control group was treated with relevant serum-free culture medium.
Figure 12
Figure 12
Cell membrane permeability effects of Dermaseptin-PH on MCF-7 cell by using SYTOX Green (1 μM) (Life technologies) at peptide concentrations from 1 to 100 μM. Positive control was obtained following incubation with 0.5% Triton X-100. Negative control was obtained following incubation with relevant serum-free culture medium. Data represent means ± SEM of 5 replicates.

Similar articles

Cited by

References

    1. Da Cunha N.B., Cobacho N.B., Viana J.F., Lima L.A., Sampaio K.B., Dohms S.S., Ferreira A.C., de la Fuente-Nunez C., Costa F.F., Franco O.L., et al. The next generation of antimicrobial peptides (AMPs) as molecular therapeutic tools for the treatment of diseases with social and economic impacts. Drug Discov. Today. 2017;22:234–248. doi: 10.1016/j.drudis.2016.10.017. - DOI - PMC - PubMed
    1. Hancock R.E., Lehrer R. Cationic peptides: A new source of antibiotics. Trends Biotechnol. 1998;16:82–88. doi: 10.1016/S0167-7799(97)01156-6. - DOI - PubMed
    1. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415:389–395. doi: 10.1038/415389a. - DOI - PubMed
    1. Bowdish D., Davidson D., Hancock R. A re-evaluation of the role of host defence peptides in mammalian immunity. Curr. Protein Pept. Sci. 2005;6:35–51. doi: 10.2174/1389203053027494. - DOI - PubMed
    1. Oppenheim J.J., Yang D. Alarmins: Chemotactic activators of immune responses. Curr. Opin. Immunol. 2005;17:359–365. doi: 10.1016/j.coi.2005.06.002. - DOI - PubMed

MeSH terms

LinkOut - more resources